The IL13 Knockout ACHN Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated from the ACHN human renal cell adenocarcinoma line, carrying a targeted disruption of the IL13 gene. This pooled format comprises a heterogeneous mixture of edited cells, providing a cost-effective and robust loss-of-function model for investigating interleukin-13 signaling in cancer biology without requiring single-cell cloning.
The parental ACHN cell line was originally derived from the pleural effusion of a 22-year-old male patient with renal cell carcinoma and is a widely used in vitro model for renal cancer research. ACHN cells maintain key characteristics of renal adenocarcinoma, including epithelial morphology and responsiveness to cytokine stimulation, making them a relevant platform for dissecting tumor cell-autonomous signaling and interactions with the microenvironment.
IL13 encodes interleukin-13, a cytokine that signals through a receptor complex of IL4R?? and IL13R??1, activating JAK1 and JAK2 to phosphorylate STAT6, as well as engaging IRS1 to stimulate PI3K/AKT signaling. IL-13 is central to Th2-type immunity, promoting IgE class switching, mucus production, and expression of chemokines like CCL11 (eotaxin) and regulators such as SOCS1. Disruption of IL13 in these cells abolishes ligand-dependent signaling, preventing STAT6 activation and downstream transcriptional events.
In the context of renal cell carcinoma, autocrine or paracrine IL-13 signaling may contribute to tumor progression by enhancing cell proliferation, survival, and immune evasion. This ACHN knockout model permits rigorous dissection of tumor-intrinsic IL-13 functions, effectively decoupling cancer cell-derived cytokine effects from those mediated by infiltrating immune cells or stromal elements. It thus enables focused analysis of JAK/STAT6 and PI3K/AKT pathway contributions to renal cancer phenotypes.
This polyclonal knockout population is ideally suited for a variety of functional assays, including Western blotting for phospho-STAT6 and total STAT6, RT-qPCR analysis of downstream targets such as CCL11 and SOCS1, cell proliferation and invasion assays, cytokine ELISA profiling, transcriptomic studies via RNA-seq, and in vivo xenograft tumor growth experiments. Primary research applications encompass investigating IL-13’s role in renal cell carcinoma biology, screening small-molecule inhibitors of the IL-13 pathway, characterizing tumor microenvironment cytokine networks, and evaluating immune checkpoint modulation. For further technical details, batch-specific characterization data, or custom project inquiries, please contact Ascent Research.
